Gregory Renza
Stock Analyst at RBC Capital
(2.24)
# 2,687
Out of 4,896 analysts
206
Total ratings
36.32%
Success rate
-0.88%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $50.54 | -30.74% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $20.98 | +23.93% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $3.15 | +153.97% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $1.36 | +267.65% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $44.86 | -10.83% | 10 | May 14, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $312 → $311 | $250.30 | +24.25% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $110.29 | +55.95% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $8.00 | +300.00% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $295.27 | +8.38% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $26.72 | +154.49% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.98 | +276.88% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $11.22 | +6.95% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $4.69 | +198.83% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $12.44 | +117.04% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $22.46 | +171.59% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $22.90 | -21.40% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $3.51 | +1,267.52% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.20 | +354.55% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $3.77 | +165.25% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $17.05 | +175.66% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $39.06 | +45.93% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $7.85 | -49.04% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.81 | +147.95% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $8.83 | +285.05% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $5.30 | +201.89% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $4.88 | +3,588.52% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.73 | +4,524.28% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.13 | +2,554.87% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $50.54
Upside: -30.74%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $20.98
Upside: +23.93%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.15
Upside: +153.97%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.36
Upside: +267.65%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $44.86
Upside: -10.83%
BeOne Medicines
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $250.30
Upside: +24.25%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $110.29
Upside: +55.95%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $8.00
Upside: +300.00%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $295.27
Upside: +8.38%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $26.72
Upside: +154.49%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.98
Upside: +276.88%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $11.22
Upside: +6.95%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $4.69
Upside: +198.83%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $12.44
Upside: +117.04%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $22.46
Upside: +171.59%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $22.90
Upside: -21.40%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $3.51
Upside: +1,267.52%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.20
Upside: +354.55%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $3.77
Upside: +165.25%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $17.05
Upside: +175.66%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $39.06
Upside: +45.93%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $7.85
Upside: -49.04%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.81
Upside: +147.95%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $8.83
Upside: +285.05%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $5.30
Upside: +201.89%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $4.88
Upside: +3,588.52%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.73
Upside: +4,524.28%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.13
Upside: +2,554.87%